Cover Image
Market Research Report

Global Drug Delivery Market - Industry Trends and Forecast to 2027

Published by Data Bridge Market Research Private Limited Product code 932717
Published Content info 542 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Drug Delivery Market - Industry Trends and Forecast to 2027
Published: March 1, 2020 Content info: 542 Pages
Description

Global drug delivery market is projected to register a substantial growth in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation

Global Drug Delivery Market, By Product Type (Oral Drug Delivery, Pulmonary Drug Delivery, Injectable Drug Delivery, Opthalmic Drug Delivery, Nasal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, Transmucosal Drug Delivery), End User (Hospitals, Community Healthcare, Home Healthcare, Clinics, Others), Distribution Channel (Hospital Pharmacies, Pharmacy Stores, Direct Tenders, Online Pharmacy), Country (U.S. Mexico, Canada, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, South Africa, Rest of Middle East & Africa), Market Trends and Forecast to 2027.

Some of the major factors contributing to the growth of the global drug delivery market are:

  • Rising prevalence of chronic disease and non-chronic disease
  • Growth in the development of biologics

Market Players

The Key Market Players for global drug delivery market are listed below:

  • Johnson & Johnson services, Inc.
  • Novartis AG
  • F. Hoffmann-la Roche Ltd
  • Bayer AG
  • Pfizer Inc.
  • 3M
  • Antares Pharma
  • GlaxoSmithKline Plc
  • Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.)
  • Nemera
  • Sanofi
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION 62

  • 1.1 OBJECTIVES OF THE STUDY 62
  • 1.2 MARKET DEFINITION 62
  • 1.3 OVERVIEW OF GLOBAL DRUG DELIVERY MARKET 82
  • 1.4 LIMITATIONS 84
  • 1.5 MARKETS COVERED 84

2 MARKET SEGMENTATION 88

  • 2.1 MARKETS COVERED 88
  • 2.2 GEOGRAPHICAL SCOPE 89
  • 2.3 YEARS CONSIDERED FOR THE STUDY 90
  • 2.4 CURRENCY AND PRICING 90
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 91
  • 2.6 MULTIVARIATE MODELLING 94
  • 2.7 PRODUCTS LIFELINE CURVE 94
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 95
  • 2.9 DBMR MARKET POSITION GRID 96
  • 2.10 VENDOR SHARE ANALYSIS 98
  • 2.11 SECONDARY SOURCES 99
  • 2.12 ASSUMPTIONS 99

3 EXECUTIVE SUMMARY 100

4 PREMIUM INSIGHTS 103

5 MARKET OVERVIEW 105

  • 5.1 DRIVERS 107
    • 5.1.1 RISING PREVALENCE OF CHRONIC DISEASE AND NON CHRONIC DISEASE 107
    • 5.1.2 GROWTH IN THE DEVELOPMENT OF BIOLOGICS 107
    • 5.1.3 TECHNOLOGICAL DEVELOPMENT 108
    • 5.1.4 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT 109
    • 5.1.5 RISING ACCEPTANCE OF SELF ADMINISTERING DRUGS 109
  • 5.2 RESTRAINTS 111
    • 5.2.1 RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS 111
    • 5.2.2 HIGH COSTS OF DRUGS 111
    • 5.2.3 STRINGENT REGULATORY SCENARIO 112
    • 5.2.4 PRODUCT RECALLS 113
  • 5.3 OPPORTUNITIES 114
    • 5.3.1 RISING DEMAND FOR BIOSIMILARS AND GENERIC DRUGS 114
    • 5.3.2 THERAPEUTIC ADVANCEMENTS 118
    • 5.3.3 TREND OF MERGER AND ACQUISITIONS AND COLLABORATIONS 118
    • 5.3.4 FOCUS ON PATIENTS' NEEDS 119
    • 5.3.5 DEVELOPING AND NEW EMERGING REVENUE POCKETS 119
  • 5.4 CHALLENGES 120
    • 5.4.1 SIDE EFFECTS OF DRUG DELIVERY SYSTEMS 120
    • 5.4.2 PATENT EXPIRY AND PATENT CLIFF 120
    • 5.4.3 ALTERNATIVES TO DRUG DELIVERY 121

6 GLOBAL DRUG DELIVERY MARKET, BY PRODUCT TYPE 123

  • 6.1 OVERVIEW 124
  • 6.2 ORAL DRUG DELIVERY 127
    • 6.2.1 BY FORM 127
      • 6.2.1.1 SOLID ORAL DRUGS 127
        • 6.2.1.1.1 TABLETS 128
        • 6.2.1.1.2 CAPSULES 128
        • 6.2.1.1.3 PILLS 128
        • 6.2.1.1.4 POWDERS 128
      • 6.2.1.2 LIQUID ORAL DRUGS 128
        • 6.2.1.2.1 SYRUPS 129
        • 6.2.1.2.2 SOLUTIONS 129
      • 6.2.1.3 semi solid oral drugs 129
        • 6.2.1.3.1 GELS 129
        • 6.2.1.3.2 EMULSIONS 129
        • 6.2.1.3.3 ELIXIRS 130
  • 6.3 INJECTABLE DRUG DELIVERY 130
    • 6.3.1 INJECTABLE DRUG DELIVERY DEVICES 131
      • 6.3.1.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES 131
        • 6.3.1.1.1 BY MATERIAL TYPE 131
        • 6.3.1.1.1.1 GLASS 131
        • 6.3.1.1.1.2 PLASTIC 131
        • 6.3.1.1.2 BY PRODUCT TYPE 132
        • 6.3.1.1.2.1 FILLABLE 132
        • 6.3.1.1.2.2 PRE-FILLED 132
        • 6.3.1.1.3 BY USABILITY 132
        • 6.3.1.1.3.1 REUSABLE SYRINGES 132
        • 6.3.1.1.3.2 DISPOSABLE SYRINGES 132
      • 6.3.1.2 SELF-INJECTION DRUG DELIVERY 133
        • 6.3.1.2.1 NEEDLE FREE INJECTORS 133
        • 6.3.1.2.2 WEARABLE INJECTORS 133
        • 6.3.1.2.3 PEN INJECTOR 133
        • 6.3.1.2.4 AUTO INJECTORS 133
        • 6.3.1.2.5 OTHERS 134
    • 6.3.2 INJECTABLE DRUG DELIVERY FORMULATIONS 134
      • 6.3.2.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS 134
      • 6.3.2.2 NOVEL DRUG DELIVERY FORMULATIONS 134
      • 6.3.2.3 LONG ACTING INJECTION FORMULATIONS 134
  • 6.4 OPHTHALMIC DRUG DELIVERY 135
      • 6.4.1.1 OCULAR DRUG DELIVERY FORMULATIONS 135
        • 6.4.1.1.1 LIQUID OCULAR DRUG DELIVERY FORMULATIONS 136
        • 6.4.1.1.1.1 SOLUTIONS 136
        • 6.4.1.1.1.2 SUSPENSIONS 136
        • 6.4.1.1.2 SEMI SOLID OCULAR DRUG DELIVERY FORMULATIONS 136
        • 6.4.1.1.2.1 GELS 136
        • 6.4.1.1.2.2 OINTMENTS 137
      • 6.4.1.2 OCULAR DRUG DELIVERY DEVICES 137
        • 6.4.1.2.1.1 DRUG COATED CONTACT LENSES 137
        • 6.4.1.2.1.2 OCULAR INSERTS 137
  • 6.5 NASAL DRUG DELIVERY 138
    • 6.5.1 NASAL DROPS 138
    • 6.5.2 NASAL SPRAYS 138
    • 6.5.3 NASAL POWDERS 138
    • 6.5.4 NASAL GELS 138
  • 6.6 TOPICAL DRUG DELIVERY 139
    • 6.6.1 TRANSDERMAL DRUG DELIVERY DEVICES 139
      • 6.6.1.1 TRANSDERMAL PATCHES 140
      • 6.6.1.2 TRANSDERMAL GELS 140
    • 6.6.2 TRANSDERMAL DRUG DELIVERY FORMULATIONS 140
      • 6.6.2.1 LIQUID TOPICAL DRUG DELIVERY FORMULATIONS 140
        • 6.6.2.1.1 SUSPENSIONS 141
        • 6.6.2.1.2 SOLUTIONS 141
      • 6.6.2.2 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS 141
        • 6.6.2.2.1 OINTMENTS 141
        • 6.6.2.2.2 CREAMS 141
        • 6.6.2.2.3 LOTIONS 141
        • 6.6.2.2.4 GELS 141
        • 6.6.2.2.5 PASTES 142
      • 6.6.2.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS 142
        • 6.6.2.3.1 POWDER 142
        • 6.6.2.3.2 SUPPOSITORS 142
  • 6.7 IMPLANTABLE DRUG DELIVERY 143
    • 6.7.1 PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES 143
    • 6.7.2 ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES 143
  • 6.8 TRANSMUCOSAL DRUG DELIVERY 144
    • 6.8.1 ORAL TRANSMUCOSAL DRUG DELIVERY 144
      • 6.8.1.1 BUCCAL DRUG DELIVERY 145
      • 6.8.1.2 SUBLINGUAL DRUG DELIVERY 145
    • 6.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY 145
      • 6.8.2.1 RECTAL TRANSMUCOSAL DRUG DELIVERY 145
      • 6.8.2.2 VAGINAL TRANSMUCOSAL DRUG DELIVERY 145
  • 6.9 PULMONARY DRUG DELIVERY 146
    • 6.9.1 METERED DOSE INHALERS (MDI) 146
    • 6.9.2 DRY POWDER INHALERS (DPI) 146
    • 6.9.3 NEBULIZERS 146
      • 6.9.3.1 JET NEBULIZERS 147
      • 6.9.3.2 ULTRASONIC NEBULIZERS 147
      • 6.9.3.3 SOFT MIST NEBULIZERS 147

7 GLOBAL DRUG DELIVERY MARKET, BY END USER 148

  • 7.1 OVERVIEW 149
  • 7.2 HOSPITALS 152
  • 7.3 HOME HEALTHCARE 152
  • 7.4 CLINICS 153
  • 7.5 COMMUNITY HEALTHCARE 153
  • 7.6 OTHERS 154

8 GLOBAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 155

  • 8.1 OVERVIEW 156
  • 8.2 DIRECT TENDERS 159
  • 8.3 HOSPITAL PHARMACIES 159
  • 8.4 PHARMACY STORES 160
  • 8.5 ONLINE PHARMACY 160

9 GLOBAL DRUG DELIVERY MARKET, BY GEOGRAPHY 161

  • 9.1 OVERVIEW 162
  • 9.2 NORTH AMERICA 167
    • 9.2.1 U.S. 179
    • 9.2.2 CANADA 188
    • 9.2.3 MEXICO 197
  • 9.3 EUROPE 206
    • 9.3.1 GERMANY 218
    • 9.3.2 FRANCE 227
    • 9.3.3 ITALY 236
    • 9.3.4 U.K. 245
    • 9.3.5 SWITZERLAND 254
    • 9.3.6 SPAIN 263
    • 9.3.7 NETHERLANDS 272
    • 9.3.8 RUSSIA 281
    • 9.3.9 TURKEY 290
    • 9.3.10 BELGIUM 299
    • 9.3.11 REST OF EUROPE 308
  • 9.4 ASIA-PACIFIC 309
    • 9.4.1 JAPAN 321
    • 9.4.2 CHINA 330
    • 9.4.3 INDIA 339
    • 9.4.4 SOUTH KOREA 348
    • 9.4.5 AUSTRALIA 357
    • 9.4.6 THAILAND 366
    • 9.4.7 MALAYSIA 375
    • 9.4.8 SINGAPORE 384
    • 9.4.9 INDONESIA 393
    • 9.4.10 PHILIPPINES 402
    • 9.4.11 REST OF ASIA-PACIFIC 411
  • 9.5 SOUTH AMERICA 412
    • 9.5.1 BRAZIL 424
    • 9.5.2 REST OF SOUTH AMERICA 433
  • 9.6 MIDDLE EAST AND AFRICA 434
    • 9.6.1 SOUTH AFRICA 446
    • 9.6.2 REST OF MIDDLE EAST AND AFRICA 455

10 GLOBAL DRUG DELIVERY MARKET, COMPANY LANDSCAPE 456

  • 10.1 COMPANY SHARE ANALYSIS: GLOBAL 456
  • 10.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 457
  • 10.3 COMPANY SHARE ANALYSIS: EUROPE 458
  • 10.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 459

11 COMPANY PROFILES 460

  • 11.1 JOHNSON & JOHNSON SERVICES, INC. 460
    • 11.1.1 COMPANY SNAPSHOT 460
    • 11.1.2 REVENUE ANALYSIS 461
    • 11.1.3 COMPANY SHARE ANALYSIS 461
    • 11.1.4 PRODUCT PORTFOLIO 462
    • 11.1.5 RECENT DEVELOPMENTS 463
  • 11.2 NOVARTIS AG 467
    • 11.2.1 COMPANY SNAPSHOT 467
    • 11.2.2 REVENUE ANALYSIS 468
    • 11.2.3 COMPANY SHARE ANALYSIS 468
    • 11.2.4 PRODUCT PORTFOLIO 469
    • 11.2.5 RECENT DEVELOPMENTS 471
  • 11.3 F. HOFFMANN-LA ROCHE LTD 476
    • 11.3.1 COMPANY SNAPSHOT 476
    • 11.3.2 REVENUE ANALYSIS 477
    • 11.3.3 COMPANY SHARE ANALYSIS 477
    • 11.3.4 PRODUCT PORTFOLIO 478
    • 11.3.5 RECENT DEVELOPMENTS 483
  • 11.4 BAYER AG 486
    • 11.4.1 COMPANY SNAPSHOT 486
    • 11.4.2 REVENUE ANALYSIS 487
    • 11.4.3 COMPANY SHARE ANALYSIS 487
    • 11.4.4 PRODUCT PORTFOLIO 488
    • 11.4.5 RECENT DEVELOPMENTS 489
  • 11.5 PFIZER INC. 493
    • 11.5.1 COMPANY SNAPSHOT 493
    • 11.5.2 REVENUE ANALYSIS 494
    • 11.5.3 COMPANY SHARE ANALYSIS 494
    • 11.5.4 BRAND PORTFOLIO 495
    • 11.5.5 RECENT DEVELOPMENTS 502
  • 11.6 3M 506
    • 11.6.1 COMPANY SNAPSHOT 506
    • 11.6.2 REVENUE ANALYSIS 507
    • 11.6.3 PRODUCT PORTFOLIO 508
    • 11.6.4 RECENT DEVELOPMENTS 509
  • 11.7 ANTARES PHARMA 510
    • 11.7.1 COMPANY SNAPSHOT 510
    • 11.7.2 REVENUE ANALYSIS 511
    • 11.7.3 PRODUCT PORTFOLIO 511
    • 11.7.4 RECENT DEVELOPMENTS 512
  • 11.8 GLAXOSMITHKLINE PLC 513
    • 11.8.1 COMPANY SNAPSHOT 513
    • 11.8.2 REVENUE ANALYSIS 514
    • 11.8.3 PRODUCT PORTFOLIO 515
    • 11.8.4 RECENT DEVELOPMENTS 518
  • 11.9 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.) 521
    • 11.9.1 COMPANY SNAPSHOT 521
    • 11.9.2 REVENUE ANALYSIS 522
    • 11.9.3 PRODUCT PORTFOLIO 522
    • 11.9.4 RECENT DEVELOPMENTS 525
  • 11.10 NEMERA 529
    • 11.10.1 COMPANY SNAPSHOT 529
    • 11.10.2 PRODUCT PORTFOLIO 529
    • 11.10.3 RECENT DEVELOPMENTS 530
  • 11.11 SANOFI 531
    • 11.11.1 COMPANY SNAPSHOT 531
    • 11.11.2 REVENUE ANALYSIS 532
    • 11.11.3 PRODUCT PORTFOLIO 532
    • 11.11.4 RECENT DEVELOPMENTS 536

12 QUESTIONNAIRE 539

13 RELATED REPORTS 542

LIST OF FIGURES

  • FIGURE 1 GLOBAL DRUG DELIVERY MARKET: SEGMENTATION 88
  • FIGURE 2 GLOBAL DRUG DELIVERY MARKET: DATA TRIANGULATION 91
  • FIGURE 3 GLOBAL DRUG DELIVERY MARKET: DROC ANALYSIS 92
  • FIGURE 4 GLOBAL DRUG DELIVERY MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 93
  • FIGURE 5 GLOBAL DRUG DELIVERY MARKET : COMPANY RESEARCH ANALYSIS 93
  • FIGURE 6 GLOBAL DRUG DELIVERY MARKET: INTERVIEW DEMOGRAPHICS 95
  • FIGURE 7 GLOBAL DRUG DELIVERY MARKET: DBMR MARKET POSITION GRID 96
  • FIGURE 8 GLOBAL DRUG DELIVERY MARKET: VENDOR SHARE ANALYSIS 98
  • FIGURE 9 GLOBAL DRUG DELIVERY MARKET: SEGMENTATION 101
  • FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL DRUG DELIVERY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2020 TO 2027 102
  • FIGURE 11 RISING PREVALENCE OF CHRONIC DISEASES AND NON CHRONIC DISEASES AND GROWTH IN THE DEVELOPMENT OF BIOLOGICS ARE EXPECTED TO BE KEY DRIVING FACTORS IN THE GLOBAL DRUG DELIVERY MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 103
  • FIGURE 12 ORAL DRUG DELIVERY IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL DRUG DELIVERY MARKET IN 2020 & 2027 103
  • FIGURE 13 NORTH AMERICA IS THE FASTEST GROWING MARKET FOR DRUG DELIVERY MANUFACTURERS IN THE FORECAST PERIOD OF 2020 TO 2027 104
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL DRUG DELIVERY MARKET 106
  • FIGURE 15 GLOBAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2019 124
  • FIGURE 16 GLOBAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2019-2027 (USD BILLION) 125
  • FIGURE 17 GLOBAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, CAGR (2020-2027) 125
  • FIGURE 18 GLOBAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, LIFELINE CURVE 126
  • FIGURE 19 GLOBAL DRUG DELIVERY MARKET: BY END USER, 2019 149
  • FIGURE 20 GLOBAL DRUG DELIVERY MARKET: BY END USER, 2019-2027 (USD BILLION) 150
  • FIGURE 21 GLOBAL DRUG DELIVERY MARKET: BY END USER, CAGR (2020-2027) 150
  • FIGURE 22 GLOBAL DRUG DELIVERY MARKET: BY END USER, LIFELINE CURVE 151
  • FIGURE 23 GLOBAL DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, 2019 156
  • FIGURE 24 GLOBAL DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION) 157
  • FIGURE 25 GLOBAL DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 157
  • FIGURE 26 GLOBAL DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 158
  • FIGURE 27 GLOBAL DRUG DELIVERY MARKET: SNAPSHOT (2019) 163
  • FIGURE 28 GLOBAL DRUG DELIVERY MARKET: BY REGION (2019) 164
  • FIGURE 29 GLOBAL DRUG DELIVERY MARKET: BY REGION (2020 & 2027) 164
  • FIGURE 30 GLOBAL DRUG DELIVERY MARKET: BY REGION (2019 & 2027) 165
  • FIGURE 31 GLOBAL DRUG DELIVERY MARKET: BY PRODUCT TYPE (2020-2027) 165
  • FIGURE 32 NORTH AMERICA DRUG DELIVERY MARKET: SNAPSHOT (2019) 167
  • FIGURE 33 NORTH AMERICA DRUG DELIVERY MARKET: BY COUNTRY (2019) 168
  • FIGURE 34 NORTH AMERICA DRUG DELIVERY MARKET: BY COUNTRY (2020 & 2027) 168
  • FIGURE 35 NORTH AMERICA DRUG DELIVERY MARKET: BY COUNTRY (2019 & 2027) 169
  • FIGURE 36 NORTH AMERICA DRUG DELIVERY MARKET: BY PRODUCT TYPE (2020-2027) 169
  • FIGURE 37 EUROPE DRUG DELIVERY MARKET: SNAPSHOT (2019) 206
  • FIGURE 38 EUROPE DRUG DELIVERY MARKET: BY COUNTRY (2019) 207
  • FIGURE 39 EUROPE DRUG DELIVERY MARKET: BY COUNTRY (2020 & 2027) 207
  • FIGURE 40 EUROPE DRUG DELIVERY MARKET: BY COUNTRY (2019 & 2027) 208
  • FIGURE 41 EUROPE DRUG DELIVERY MARKET: BY PRODUCT TYPE (2020-2027) 208
  • FIGURE 42 ASIA-PACIFIC DRUG DELIVERY MARKET: SNAPSHOT (2019) 309
  • FIGURE 43 ASIA-PACIFIC DRUG DELIVERY MARKET: BY COUNTRY (2019) 310
  • FIGURE 44 ASIA-PACIFIC DRUG DELIVERY MARKET: BY COUNTRY (2020 & 2027) 310
  • FIGURE 45 ASIA-PACIFIC DRUG DELIVERY MARKET: BY COUNTRY (2019 & 2027) 311
  • FIGURE 46 ASIA-PACIFIC DRUG DELIVERY MARKET: BY PRODUCT TYPE (2020-2027) 311
  • FIGURE 47 SOUTH AMERICA DRUG DELIVERY MARKET: SNAPSHOT (2019) 412
  • FIGURE 48 SOUTH AMERICA DRUG DELIVERY MARKET: BY COUNTRY (2019) 413
  • FIGURE 49 SOUTH AMERICA DRUG DELIVERY MARKET: BY COUNTRY (2020 & 2027) 413
  • FIGURE 50 SOUTH AMERICA DRUG DELIVERY MARKET: BY COUNTRY (2019 & 2027) 414
  • FIGURE 51 SOUTH AMERICA DRUG DELIVERY MARKET: BY PRODUCT TYPE (2020-2027) 414
  • FIGURE 52 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: SNAPSHOT (2019) 434
  • FIGURE 53 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY COUNTRY (2019) 435
  • FIGURE 54 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY COUNTRY (2020 & 2027) 435
  • FIGURE 55 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY COUNTRY (2019 & 2027) 436
  • FIGURE 56 MIDDLE EAST AND AFRICA DRUG DELIVERY MARKET: BY PRODUCT TYPE (2020-2027) 436
  • FIGURE 57 GLOBAL DRUG DELIVERY MARKET: COMPANY SHARE 2019 (%) 456
  • FIGURE 58 NORTH AMERICA DRUG DELIVERY MARKET: COMPANY SHARE 2019 (%) 457
  • FIGURE 59 EUROPE DRUG DELIVERY MARKET: COMPANY SHARE 2019 (%) 458
  • FIGURE 60 ASIA-PACIFIC DRUG DELIVERY MARKET: COMPANY SHARE 2019 (%) 459
Back to Top